Based on the continuing education webinar presented by Ann Marie Woyma, DVM.*
Surgical bleeding remains one of the most significant challenges facing veterinary practitioners. Extended bleeding episodes increase anesthesia duration, elevate patient risk, and can transform routine procedures into complex cases requiring emergency intervention.
Despite advances in surgical techniques, hemostatic control continues to rely heavily on methods developed decades ago. Recent developments in polymer-based hemostatic technology like Vetigel® hemostatic gel offer new approaches, but how do they compare to established methods?
How Do Traditional and Modern Hemostatic Agents Work?
Veterinary practitioners have multiple hemostatic approaches available, each with distinct mechanisms of action. Understanding these differences is essential for selecting the right product for each clinical scenario.
Traditional Matrix-Based Hemostatic Agents
Cellulose-based products, gelatin sponges, and collagen matrices provide scaffolding for natural clot formation through the patient’s coagulation cascade.
Advantages: Well-established safety profile, cost-effective for routine procedures, familiar to most practitioners
Limitations: Requires direct blood contact for activation, integrates with patient’s clot (removal disrupts hemostasis), variable effectiveness with high-pressure bleeding, can impair surgical visualization
Modern Polymer-Based Hemostatic Technology
Plant-based polymers like Vetigel hemostatic gel create mechanical barriers through ionic crosslinking, independent of natural clotting mechanisms.
Advantages: Immediate hemostatic effect regardless of patient coagulation status, non-integrating (removable without disturbing hemostasis), effective against high-pressure arterial bleeding, maintains clear surgical field
Limitations: Higher cost per application, requires specific application technique, limited long-term comparative studies
Clinical Evidence: A study comparing polymer-based agents like the Vetigel product showed 94% immediate hemostasis rates compared to 67% for traditional matrix agents in high-pressure bleeding scenarios.
Which Hemostatic Agent Should You Choose for Different Species?
Species-specific factors significantly impact hemostatic agent selection and effectiveness in veterinary surgery.
Canine Surgical Bleeding Control
Dogs tolerate most hemostatic agents well, but patient size impacts cost-effectiveness. Large breed surgical procedures may require multiple applications of any hemostatic product.
Feline Surgical Considerations
Cats show particular sensitivity to prolonged anesthesia, making rapid hemostasis especially critical. Smaller surgical sites may favor precision-application products over broad-coverage traditional agents.
Exotic Animal Hemostasis
Limited research exists on hemostatic agent safety in exotic species. Consultation with exotic veterinary specialists is recommended when considering newer technologies.
What Are the Best Hemostatic Agents for Common Veterinary Procedures?
Matching the right hemostatic technology to specific surgical procedures maximizes both clinical outcomes and cost-effectiveness.
Enucleation Surgery Bleeding Control
Clinical Comparison: Average procedure time with traditional methods (45-60 minutes) versus Vetigel hemostatic gel polymer technology (35-45 minutes). Post-operative complications: Traditional approach (15% discharge issues) versus Vetigel product-based hemostasis (3% discharge issues) when properly removed.
Economic Analysis: Higher product cost is offset by reduced anesthesia time and fewer complications.
Dental Extraction Bleeding Control
Extraction sites in highly vascular oral tissue present difficult access for traditional ligation. Full-mouth extractions show 30% reduction in total anesthesia time with advanced hemostatic protocols using products like Vetigel hemostatic gel.
Mass Removal and Soft Tissue Surgery
Small masses: Traditional methods often sufficient Large masses/mastectomies: Advanced agents like Vetigel hemostatic gel provide better coverage Vascular masses: The Vetigel product shows superior high-pressure bleeding control.
When Should Your Practice Use Traditional vs Modern Hemostatic Agents?
Developing clear selection criteria helps optimize both clinical outcomes and practice profitability based on case-specific factors.
When Traditional Methods Remain Optimal:
- Routine procedures with minimal bleeding expected
- Cost-sensitive cases where bleeding is easily controlled
When Advanced Technology Provides Value:
- High-risk patients who cannot tolerate blood loss
- Procedures with historically difficult hemostatic control
- Emergency situations requiring immediate bleeding cessation
- Cases where surgical visualization is critical
- Coagulopathic patients or those on anticoagulants
Products like Vetigel hemostatic gel excel in these scenarios due to their coagulation-independent mechanism and rapid action.
Economic Considerations by Practice Type:
- High-Volume/Low-Cost Practices: Traditional agents for routine cases, Vetigel hemostatic gel for complications
- Specialty Practices: The Vetigel product as standard for complex procedures
- Emergency Clinics: Stock both options based on case severity assessment
How to Successfully Integrate Modern Hemostatic Agents into Your Practice
Transitioning to advanced hemostatic technology requires systematic implementation rather than wholesale practice changes. This phased approach maximizes success while controlling costs.
Phase 1: Assessment (Months 1-2)
Audit current hemostatic challenges in your practice. Calculate true cost of extended procedures due to bleeding complications. Identify 2-3 procedure types for initial trial.
Phase 2: Selective Implementation (Months 3-6)
Train team on proper application techniques for Vetigel hemostatic gel. Use advanced products for pre-identified challenging cases. Document outcomes and time savings.
Phase 3: Protocol Development (Months 6-12)
Establish clear criteria for product selection. Develop cost-effective protocols based on case type. Train entire surgical team on decision matrix.
What Clinical Evidence Should Guide Your Decisions?
Evidence-based hemostatic agent selection requires tracking specific metrics in your own practice to inform product decisions.
Track These Clinical Efficacy Metrics:
- Time to hemostasis achievement
- Total surgical duration
- Post-operative bleeding complications
- Patient recovery indicators
Assess Economic Impact:
- Product cost per procedure
- Anesthesia time savings value
- Complication reduction cost benefit
- Overall procedure profitability impact
Real-World Results: Multi-Modal Approach Case Study
A 1,200-case veterinary facility implemented a tiered hemostatic protocol:
Protocol: Routine procedures used traditional matrix agents, complex/high-risk cases used Vetigel hemostatic gel polymer technology, emergency bleeding received immediate Vetigel product deployment.
Results After 12 Months: 23% reduction in average surgical time for complex cases, 67% decrease in post-operative bleeding complications, 15% improvement in surgical suite efficiency, positive ROI achieved within 8 months.
Making Smart Hemostatic Decisions for Your Practice
Modern hemostatic technology offers genuine advantages for specific clinical scenarios, but success requires thoughtful integration rather than wholesale replacement of established methods. The key lies in matching the right technology to the right clinical situation while considering both medical and economic factors.
Practices that develop systematic approaches to hemostatic product selection report improved surgical efficiency, reduced complications, and enhanced team confidence in managing bleeding challenges.
Ready to optimize surgical bleeding control in your practice?
Contact us to learn more about implementing evidence-based hemostatic protocols.
*Dr. Wyoma was paid by Zomedica, Inc. for presenting this webinar. Watch the full presentation here.
© 2025 Zomedica Inc. All rights reserved.
Vetigel is a registered trademark of Cresilon, Inc.
